Downgrade and Index Shifts Put Doximity Back Under the Microscope

Doximity (DOCS) is back in focus after BofA Securities cut its rating and revenue outlook, citing uncertainty around the company’s AI driven growth plans and potential pressure on margins from higher investment spending.

At a share price of $20.59, Doximity has seen short term share price momentum soften. The 30 day share price return is down 3.79% and the year to date share price return is down 52.44%, while the 1 year total shareholder return has fallen 66.43%. Recent index moves from multiple Russell growth indices into value oriented benchmarks reflect how the market is reassessing its profile after weaker fiscal 2027 revenue guidance and the latest analyst downgrade.

If Doximity's shift toward AI tools has your attention, it may be a good moment to compare it with other healthcare focused AI opportunities using our stock screener, starting with 41 healthcare AI stocks.

With Doximity now trading at a discount to some analyst targets and carrying a higher value score, investors are asking a key question: is this a reset that leaves upside on the table, or is the market already pricing in its next phase of growth?

Most Popular Narrative: 38.9% Undervalued

Against Doximity's last close at $20.59, the most followed narrative on the stock is working off a fair value estimate of $33.70, creating a sizable valuation gap that has caught investors’ attention after the recent downgrade.

What I like about Doximity is that there really is a very high viewership / user base of active practicing Physicians in the US and that is not invaluable and definitely could be monetized perhaps more efficiently. I also think that Doximity offers a lot of interesting tools for Physicians, a lot of which are free and really marketed towards Physicians who are more in private practice. It is a little bit unclear how much value that provides given that most Physicians and practitioners these days are employed and not in private practice. Lately I have also tried some of their clinical AI tools and have been surprisingly impressed by how good they are and the quality. They are up against tight competition in open evidence in this area, but I will say that they have known brand recognition, wired usership, and lately I have been impressed by their product quality, all of which portend possibly good things to come from docs (Practicing tech focused physician here).

The narrative backing that $33.70 figure leans heavily on Doximity's physician reach, its AI workflow tools, and expectations for steady revenue growth and margins. Curious which financial assumptions and profit multiple sit underneath that view, and how they connect to its healthcare software model and projected cash generation? The full story joins those pieces together in a way the recent share price slide does not.

Result: Fair Value of $33.70 (UNDERVALUED)

However, this Doximity narrative could be tested if physician engagement softens or if AI tools fail to translate into revenue and profit at the implied assumptions.

Next Steps

With sentiment on Doximity split between concern and cautious optimism, now is a good time to review the facts yourself rather than rely on headlines. Then weigh those 1 or more potential upsides by checking the 2 key rewards

Looking for more investment ideas beyond Doximity?

If you are reassessing Doximity, do not stop there. Broaden your watchlist with other focused ideas that match your risk level and income goals.

• Target potential mispricings by scanning companies that look attractively valued on fundamentals using the 42 high quality undervalued stocks.
• Boost the income side of your portfolio by reviewing companies in the 9 dividend fortresses that prioritize meaningful cash returns to shareholders.
• Dial down risk by focusing on resilient businesses screened through the 72 resilient stocks with low risk scores before sentiment shifts again.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.